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Injectable Hydrogel Properties Influence Infarct Expansion and Extent of
Postinfarction Left Ventricular Remodeling in an Ovine Model
Abstract
A recent trend has emerged that involves myocardial injection of biomaterials, containing cells or
acellular, following myocardial infarction (MI) to influence the remodeling response through both
biological and mechanical effects. Despite the number of different materials injected in these
approaches, there has been little investigation into the importance of material properties on therapeutic
outcomes. This work focuses on the investigation of injectable hyaluronic acid (MeHA) hydrogels that
have tunable mechanics and gelation behavior. Specifically, two MeHA formulations that exhibit similar
degradation and tissue distribution upon injection but have differential moduli (∼8 versus ∼43 kPa) were
injected into a clinically relevant ovine MI model to evaluate the associated salutary effect of
intramyocardial hydrogel injection on the remodeling response based on hydrogel mechanics. Treatment
with both hydrogels significantly increased the wall thickness in the apex and basilar infarct regions
compared with the control infarct. However, only the higher-modulus (MeHA High) treatment group had a
statistically smaller infarct area compared with the control infarct group. Moreover, reductions in
normalized end-diastolic and end-systolic volumes were observed for the MeHA High group. This group
also tended to have better functional outcomes (cardiac output and ejection fraction) than the lowmodulus (MeHA Low) and control infarct groups. This study provides fundamental information that can
be used in the rational design of therapeutic materials for treatment of MI.
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L

eft ventricular (LV) remodeling caused by a myocardial infarction (MI) is responsible for almost 70% of the 5 million
cases of heart failure that have occurred in the United States in
recent years (1). Early infarct expansion or stretching has been
associated with poor long-term prognosis (2–4) and has been
identiﬁed as the mechanical phenomenon that initiates and sustains the process of adverse post-MI LV remodeling that leads to
heart failure (5–10). Infarct expansion causes abnormal stress
distribution in myocardial regions outside the infarction, especially in the adjacent borderzone region, putting this region at
a mechanical disadvantage. With time, increased regional stress is
the impetus for several maladaptive biologic processes, such as
myocyte apoptosis and matrix metalloproteinase activation, that
inherently alter the contractile properties of normally perfused
myocardium (11, 12). Once initiated, these maladaptive processes
lead to a heart failure phenotype that is difﬁcult to reverse by
medical or surgical means.
We have demonstrated that ventricular restraint early after
MI reduces infarct expansion and limits long-term global LV remodeling in large-animal infarction models (10, 13–16). To circumvent the surgical placement of restraining devices early postMI, our group and others have begun to explore the use of
injectable materials to limit infarct expansion and normalize the
regional stress distribution (17–26). Such an approach offers the
potential for a noninvasive, catheter-based treatment that could be
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administered early post-MI to attenuate the remodeling process
and prevent the development of heart failure. Despite the range of
material types and properties that have been injected, no studies
have systematically investigated the effect of material properties
(e.g., mechanics) on structural and functional outcomes. Such
information will be extremely important in developing the optimal material for preventing infarct expansion and the associated
remodeling.
This study focuses on the assessment of injectable modiﬁed
hyaluronic acid hydrogels to stiffen/thicken the infarct area to
limit the associated borderzone expansion, limit LV dilation, and
improve global function in an established, clinically relevant ovine
infarction model. Speciﬁcally, to eliminate mass loss and tissue
distribution as variables, injectable formulations of hyaluronic
acid hydrogels were designed that have similar degradation and
gelation behavior but have varied mechanical properties.
Results
Hydrogel Mechanics Are Dependent on the Extent of Modiﬁcation and
Initiator Parameters. Two methacrylated hyaluronic acid macro-

mers (MeHA) with varying amounts of methacrylate substitution were synthesized. The extent of modiﬁcation was found to
be ∼30% (MeHA Low) or ∼60% (MeHA High) by 1H NMR.
Hydrogels were prepared from the macromers (maintained at
4% by weight) upon combination with the bicomponent redox
initiation system of ammonium persulfate (APS) and N,N,N′,N′tetramethylethylenediamine (TEMED) (Fig. S1). Rheometry
was used to monitor the storage (G’, deﬁned as the fourth consecutive point with <1% change) and loss modulus (G’’) of
hydrogels formed from the different macromer and initiator
combinations (Fig S2 for a representative time sweep curve). A
signiﬁcant difference between the G’ of the two hydrogels formed
with identical initiator concentrations was observed, as was a signiﬁcant difference between hydrogels formed from the same
macromer but different initiator concentrations (Fig. 1A). As
expected, the time for gelation onset (i.e., G’>G”) decreased
as the initiator concentration increased and ranged from ∼2.5–
4.5 min (Fig. 1B). Importantly, the time for gelation was not dependent on the MeHA formulation (i.e., MeHA High versus
MeHA Low).
The delivery and penetration of the hydrogel (with dye for
visualization) was evaluated by injecting the hydrogel into the
apical region of explanted ovine LV tissue. A greater distribution
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A recent trend has emerged that involves myocardial injection
of biomaterials, containing cells or acellular, following myocardial infarction (MI) to inﬂuence the remodeling response through
both biological and mechanical effects. Despite the number of
different materials injected in these approaches, there has been
little investigation into the importance of material properties on
therapeutic outcomes. This work focuses on the investigation of
injectable hyaluronic acid (MeHA) hydrogels that have tunable
mechanics and gelation behavior. Speciﬁcally, two MeHA formulations that exhibit similar degradation and tissue distribution
upon injection but have differential moduli (∼8 versus ∼43 kPa)
were injected into a clinically relevant ovine MI model to evaluate
the associated salutary effect of intramyocardial hydrogel injection on the remodeling response based on hydrogel mechanics.
Treatment with both hydrogels signiﬁcantly increased the wall
thickness in the apex and basilar infarct regions compared with
the control infarct. However, only the higher-modulus (MeHA High)
treatment group had a statistically smaller infarct area compared
with the control infarct group. Moreover, reductions in normalized
end-diastolic and end-systolic volumes were observed for the MeHA
High group. This group also tended to have better functional outcomes (cardiac output and ejection fraction) than the low-modulus
(MeHA Low) and control infarct groups. This study provides fundamental information that can be used in the rational design of therapeutic materials for treatment of MI.

Fig. 1. Hydrogel mechanical properties and gelation time behavior. (A) Storage modulus and (B) gelation onset time for various macromer (MeHA Low or
High) and initiator [5.0 mM/5.0 mM or 12.5 mM/6.25 mM APS (A)/TEMED (T)] combinations. n = 3 per group. Data are presented as mean ± SD. **P < 0.01.
(C and D) Explanted tissue with 4% by weight MeHA High (outlined with dashed line) gelled with (C) 5.0 mM APS/5.0 mM TEMED or (D) 12.5 mM APS/6.25 mM
TEMED, showing differences in gel distribution based on initiator concentrations. (Scale bars, 10 mm.) (E) Representative H&E-stained image of the cardiac
tissue at the apex of a MeHA High gel (labeled “G”)-treated infarct 24 h postinjection, demonstrating integration with tissue. (Scale bar, 100 μm.)

of the hydrogel in the tissue was observed with hydrogels formed
with a lower initiator concentration and slower gelation time
than with hydrogels formed with a higher initiator concentration
and faster gelation (Fig. 1 C and D). The high initiator concentration also led to a more rapid increase in viscosity, making
the hydrogel more difﬁcult to inject. Based on these ﬁndings, the
5.0 mM APS and 5.0 mM TEMED initiator combination was
selected for all remaining studies. Importantly, gel distribution
was not dependent on the MeHA formulation, as long as the initiator concentration was constant. When the hydrogel was injected in vivo and assessed 24 h post-MI (Fig. 1E), histological
staining demonstrates a clear integration of the gel within the
tissue and distribution throughout cell layers (Fig. 1E).
Furthermore, bulk hydrogels formed from these macromer/
initiator combinations lost less than 25% of their mass after 20 wk
in PBS at 37 °C [as measured using the uronic acid assay (27)], and
there was no statistically signiﬁcant difference in the overall percentage of hyaluronic acid release or proﬁles throughout degradation (Fig. 2A). A decrease in the modulus of bulk hydrogels,
especially with MeHA High, is noted with time (Fig. S3). Cytotoxicity was evaluated through exposure of seeded human mesenchymal stem cells to sterilized bulk hydrogels (formed using the
same initiation conditions) in a Transwell format for up to 3 d; no
differences were observed with any of the gels compared with
unexposed controls (Fig. S4).
Hydrogel Injection Impacts Mechanics of Cardiac Tissue. To conﬁrm
further that the differences in hydrogel mechanics were maintained upon injection into cardiac tissue, the mechanics of bulk
hydrogels alone, explanted cardiac tissue alone, and hydrogel/
tissue composites were assessed. Under compression, the modulus of untreated cardiac tissue was 5.8 ± 1.5 kPa, whereas the
bulk hydrogels had moduli of 7.7 ± 1.0 kPa and 43.0 ± 12.3 kPa
for MeHA Low and MeHA High, respectively. The modulus of
the tissue/hydrogel composite was greater than explanted cardiac
11508 | www.pnas.org/cgi/doi/10.1073/pnas.1004097107

tissue alone for the MeHA High group but not for the MeHA
Low group (Fig. 2B). Speciﬁcally, with the MeHA Low gel there
was no statistical difference in the modulus between the cardiac
tissue and the composite; however, there was a statistically signiﬁcant increase in modulus with the MeHA High composite
when compared with normal cardiac tissue. Similar trends were
observed when the tissue/hydrogel composites underwent uniaxial tensile testing in the longitudinal direction (Fig. S5).
Hydrogel Injection Maintains Normal Tissue Thickness and Reduces
Infarct Size Depending on Modiﬁcation. Injection of the MeHA

hydrogels 30 min after infarction (Fig. S6 shows a representative
injection pattern) led to maintenance of tissue thickness compared with control infarct samples, as evident upon sacriﬁce at
8 wk (Fig. 3 A–C). The regional thickness from the apex to the base
was quantiﬁed and demonstrated signiﬁcant differences in tissue
thickness for MeHA High and MeHA Low hydrogel injections in
the apex (7.02 and 6.54 mm, respectively) and basilar infarct (7.15
and 6.96 mm, respectively) regions, compared with control infarct
apex (2.13 mm) and basilar infarct (4.89 mm) regions (Fig. 3D).
This prevention of tissue thinning also is evident upon examination of the representative histological images in Fig. 4. Magniﬁed images of samples with MeHA High (Fig. 4D and Fig.
S7D) and MeHA Low (Fig. 4E and Fig. S7E) treatment show
that the gels are present and maintain their integration with the
tissue at 8 wk.
The length of abnormal motion in the anteroapical wall immediately after coronary occlusion and before injection was
similar in all groups, indicating that the stimulus for remodeling
(i.e., initial infarct size) was comparable among the three groups
(Fig. 5A). However, the infarct area at the time of sacriﬁce was
smaller with MeHA treatment (23.9% MeHA High, P < 0.05, and
26.4% MeHA Low) than in the control infarct (28.6%), indicating
that the treatment groups experienced less infarct expansion
during the 8-wk follow-up period (Fig. 5A). The nonstatstically
Ifkovits et al.

signiﬁcant trend toward smaller lengths of abnormal motion in the
anteroapical wall motion abnormality in the MeHA High group
lends support to this conclusion (Table S1).
Hydrogel Injection Attenuates LV Dilation and Improves Cardiac
Function Depending on Hydrogel Mechanics. Real-time 3D echo-

cardiography was used to assess the LV dimensions and cardiac
function for each animal before and immediately after (i.e., baseline) infarction. The normalized end-diastolic volume (NEDV) and
normalized end-systolic volume (NESV) increased for all groups
after 2 wk, with the MeHA High treatment group tending to have
the smallest changes in volume (Table S1). A similar trend was
observed after 8 wk, with the MeHA High treatment group again
demonstrating an improvement (i.e., lower) in NEDV (1.7; Fig. 5B)
and NESV (1.9; Fig. 5B) compared with the infarct control (2.1
and 2.4, respectively) and the MeHA Low treatment group (2.1 and
2.5, respectively). This improvement was even more dramatic
upon stress testing with dobutamine (2.5 and 5.0 mg·kg−1min−1),
which was conducted before sacriﬁce (Table S1).
The cardiac output was reduced for all groups at 2 and 8 wk
following MI, although this difference was statistically different
from the baseline only for the control infarct group (Fig. 5C and
Table S1). A reduction in the ejection fraction (EF) at 2 and 8 wk
also was observed for all groups relative to their respective baseline values (Fig. 5C and Table S1). Stress testing before sacriﬁce
demonstrated a greater improvement in EF of the MeHA High
treatment group (Table S1).
Ifkovits et al.

Fig. 3. Hydrogel treatment inﬂuences myocardial wall thickness. Representative samples of (A) control infarct (n = 9), (B) MeHA High treatment
(n = 6), and (C) MeHA Low treatment (n = 5) 8 wk post-MI and hydrogel
injection. (D) Quantiﬁed regional tissue thicknesses at 8 wk (n = 5 for Normal). Data are presented as mean ± SEM. *P < 0.05 compared with all other
groups in the same region. (Scale bar, 10 mm.)

Discussion
The LV remodeling that occurs post-MI is a complex process,
and increased understanding of this process, as well as of the
impact of various treatment paradigms, is needed to develop
valuable therapies to improve patient outcomes and welfare. LV
remodeling evolves with time post-MI to involve myocardium
more remote from the infarct in a process known as “borderzone
expansion” (6, 11, 12, 15). The reduced wall thickness in the
infarct region and a global change to a more spherical geometry
correspond to increases in wall stress (6, 11, 12). These alterations increase the mechanical burden on the injured heart and
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Fig. 2. Hydrogel degradation and compressive mechanics. (A) MeHA High
(circle, solid line, n = 3) and MeHA Low (square, dotted line, n = 3) degradation
with time. The percentage of hyaluronic acid release was quantiﬁed with the
uronic acid (a by-product of hyaluronic acid degradation) assay. The vertical
dashed line represents the addition of 100 U/mL exogenous hyaluronidase at
20 wk to initiate complete degradation. (B) Mechanical properties of cardiac
tissue, MeHA hydrogel, and hydrogel/tissue composite. n = 5 per group. Data
are presented as mean ± SD. *P < 0.05 compared with cardiac tissue, #P < 0.05
compared with MeHA Low for the respective condition.

Fig. 4. Histological images at 8 wk post-MI and injection. Representative
H&E-stained samples of (A) control infarct, (B and D) MeHA High, and (C and
E) MeHA Low treatment in which the gel (labeled “G”) stains purple. (Scale
bar, 1 mm in A–C, 100 μm in D and E.)

PNAS | June 22, 2010 | vol. 107 | no. 25 | 11509

Fig. 5. Quantiﬁed infarct dimensions, in vivo volume, and functional metrics for control infarct (n = 9), MeHA High treatment (n = 6), and MeHA Low
treatment (n = 5). (A) Initial infarct length and infarct area at 8 wk. (B) NEDV
and NESV. (C) Cardiac output and EF. Data are presented as mean ± SEM.
*P < 0.05 versus control infarct; #P < 0.05 versus respective baseline value.

initiate maladaptive biological processes that act together to
produce heart failure (11, 12). Although recent data have demonstrated that injectable materials can affect the post-MI LV
remodeling (17–24, 26, 28), only a few groups (23, 25, 26) have
evaluated the impact of acellular intramyocardial injections in
large-animal models of MI (e.g., swine or ovine). Furthermore,
the inﬂuence of speciﬁc material properties on the associated LV
remodeling response has not been explored experimentally and
is not well understood. This lack of information is caused in
part by the difﬁculty in developing materials that can be used
to investigate systematically the inﬂuence of one property (e.g.,
mechanics) without altering other potentially confounding parameters (e.g., mass loss).
In this study, we investigated hyaluronic acid hydrogels in which
mechanical properties are modiﬁed through a simple alteration in
the number of reactive methacrylate groups (i.e., MeHA Low
versus MeHA High) on the MeHA macromer, a change that is
11510 | www.pnas.org/cgi/doi/10.1073/pnas.1004097107

made easily during synthesis. After crosslinking with the redox
initiation system, the extent of modiﬁcation leads to variations in
the crosslinking density of the hydrogels, and these variations correlate with changes in bulk mechanical properties while maintaining the same concentration of the material. Changes in the initiator
concentration (i.e., onset of gelation) led to variations in the distribution of the hydrogel within the myocardial tissue, another
parameter that may be important in therapy development as well as
in the mechanics of a speciﬁc MeHA formulation. However, the
time for gelation did not depend on the extent of methacrylation.
Notably, mass loss also did not differ between the two MeHA
formulations. Although the hydrogels undergo a small amount of
bulk hydrolytic degradation (because of ester bonds in the methacrylate group), and the compressive moduli of the hydrogels
change moderately with time, they remain greater than (MeHA
High) or similar to (MeHA Low) cardiac tissue even after 8 wk of in
vitro degradation. Thus, this system allows investigation of the inﬂuence of hydrogel mechanics on the resulting therapeutic outcomes for treating MI, without variations in material amount,
degradation, or tissue distribution to confound the ﬁndings.
Investigation of the mechanics of cardiac tissue before and
after injection of the hydrogels revealed an increased modulus
with hydrogel injection, dependent on the MeHA modiﬁcation.
A constant initiator system of 5.0 mM APS/5.0 mM TEMED
was selected to maximize material distribution at each injection
site. The injection process leads to a series of hydrogel pockets
that distribute from the injection point, making it difﬁcult to
obtain uniform samples for composite material testing. Thus,
compression was used to minimize non-uniformity of the samples, and it was possible to core the samples that appeared uniform. Similar trends were observed upon uniaxial tensile testing
of tissue/hydrogel composites in the longitudinal direction. However, because of the thickness of the wall, samples were isolated
from the midwall, leading to variability in ﬁber angle that further
contributed to the observed variations. Histological evaluation of
a hydrogel/tissue composite at 24 h postinjection in vivo demonstrated stable gel formation and integration of the gel within
the tissue, and this stability still was observed even at 8 wk postinjection. Thus, the stability of the materials indicates that the
primary difference between the two groups was the mechanical
properties of the hydrogel. Furthermore, the cellular response
to MeHA is very limited, with no evidence of increased macrophage or myoﬁbroblast inﬁltration. The change in infarct expansion and functional properties appear to relate to the
properties of the injectate rather than a biologic response to the
material. A ﬁnite element simulation of the theoretical impact of
injection of a material into the myocardium after MI illustrates
the suspected potential of intramyocardial stiffening in reducing
stress. Furthermore, stiffer materials were shown to bear more
of the load in the remote and borderzone regions, resulting in
a decrease in stresses within these regions (28). Moreover, using
a closed-loop lumped-parameter model of the ovine cardiovascular system, we also have demonstrated that a reduction in
compliance in the infarct area (i.e., infarct stiffening) should
reduce dilation of the LV and improve EF (29). For this reason,
speciﬁc formulations were investigated to form hydrogel/tissue
composites that have similar (MeHA Low) and greater (MeHA
High) moduli than native cardiac tissue. Hydrogels were injected
30 min postinfarction into 20 injection sites in the apex and
borderzone region, and outcomes were assessed after 2 and 8 wk
and by dobutamine stress evaluation immediately before sacriﬁce. To limit animal mortality, we chose to intervene at 30 min
postinfarction; this timing probably is faster than could be achieved clinically because the average time from onset of symptoms
to hospital presentation averages 2–6 h (30, 31). However, recent
reports also have demonstrated attenuation of LV remodeling
with polymer injection several weeks after infarct (32, 33). Future work will evaluate the impact of MeHA treatment time and
Ifkovits et al.
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This study evaluates the impact in vivo of the properties of an
injectable material on the post-MI LV remodeling response and
provides fundamental information that can be used in developing hydrogels for treatment of LV remodeling. However,
further work to determine the impact of hydrogel degradation
(i.e., changes in material properties with time) is needed. Moreover, the timing of therapy (e.g., acute versus chronic), mode of
delivery (e.g., via a catheter), and possible encapsulation of cells or
drugs should be investigated to develop an optimal system for
clinical use in the treatment of MI.
Materials and Methods
The animals used in this work received care in compliance with the protocols
approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania in accordance with the guidelines for humane care
(National Institutes of Health Publication 85-23, revised 1996).
Macromer Synthesis and Characterization. MeHA was synthesized as previously described (38). Brieﬂy, sodium hyaluronate (74 kDa; Lifecore) was
dissolved at 1% by weight in deionized water and reacted with methacrylic
anhydride (Sigma) at pH 8.0 on ice for 24 h with varied amounts of methacrylic anhydride to inﬂuence the ﬁnal macromer methacrylation. The
macromer was puriﬁed via dialysis (molecular weight cutoff, 6–8 kDa)
against deionized water for 72 h and lyophilized. 1H NMR (Bruker) was used
to determine the % methacrylation.
In general, MeHA (4% by weight) was dissolved in PBS with various
concentrations of APS (5.0 or 12.5 mM; Sigma) and TEMED (5.0 or 6.25 mM;
Sigma). Gelation onset (n = 3) was quantiﬁed by monitoring the storage (G’)
and loss (G’’) moduli with time using an AR2000ex Rheometer (TA Instruments) at 37 °C under 1% strain and 1 Hz in a cone and plate geometry (1°,
20-mm diameter). MeHA/APS and MeHA/TEMED solutions were loaded into
different barrels of a dual-barrel syringe and crosslinked by expulsion and
mixing from the syringe. Compression testing was completed on hydrated
samples (5-mm diameter; n = 3) using a Dynamic Mechanical Analyzer (Q800;
TA Instruments) at a strain rate of 10% min−1. Degradation (n = 3 per time
point) in PBS at 37 °C was monitored using a uronic acid assay (27), and
100 units of exogenous hyaluronidase per mL PBS was added at 20 wk for
complete degradation of the hydrogels. (Methods of cytotoxicity evaluation
are given in SI Materials and Methods.) For in vivo assessment, the lyophilized form of MeHA was sterilized by exposure to germicidal UV light for 1 h
and subsequently dissolved in sterile PBS. APS and TEMED solutions were
sterile ﬁltered before use in vivo.
Explanted Tissue. The delivery and penetration of the injected hydrogel into
normal (not infarcted) myocardial tissue was investigated using explanted
ovine myocardial tissue from the LV apex (i.e., the intended infarct region).
For visualization purposes, 125 μM methacryloxethyl thiocarbamoyl rhodamine B was added. This dye is macroscopically visible and crosslinks into the
hydrogel. To conﬁrm gelation within the tissue, 0.3 mL of the macromer/
initiator solution with dye was injected into the LV apex. After 30 min, biopsy punches were used to remove 5-mm-diameter disks of tissue or tissue
containing hydrogel composite for compression testing (n = 5 per group
from multiple samples from two hearts), as above. (Methods of uniaxial
tensile testing are detailed in SI Materials and Methods.)
Infarction Model and in Vivo Assessment. A clinically relevant ovine model of
infarction and LV remodeling was used to assess the impact of the injected
hydrogels (23). Twenty-one adult male Dorset sheep (35–40 kg) were
anesthetized. The arterial, ventricular, and pulmonary artery pressures
and electrocardiogram were monitored continuously throughout the
procedure. A left thoracotomy was performed to expose the heart.
Baseline echocardiographic and hemodynamic data were obtained. Infarction was induced via ligation of the left anterior descending and the
second diagonal coronary artery to create an infarct the basal extent of
which was 40% of the distance from the apex to the base of the heart.
This procedure previously demonstrated the creation of a reproducible,
moderately sized infarct involving ∼20% of the LV mass at the anteroapex (39).
Animals were assigned to the following three cohorts: infarct control
(n = 9), MeHA High (n = 7), and MeHA Low (n = 5). Historical data of normal
(noninfarct) tissue thickness was used for comparisons. Cohorts receiving
MeHA treatment received 20 injections of 0.3-mL macromer/initiator solution at 3 min postmixing immediately following the echocardiograph at

PNAS | June 22, 2010 | vol. 107 | no. 25 | 11511

MEDICAL SCIENCES

infarct reperfusion status on LV remodeling. This MI model involves a permanent occlusion, which generally is associated with
a more profound remodeling stimulus (34, 35) than in reperfused
infarct models that have been used to evaluate the impact of
other injectable materials with reperfusion (17, 25, 36).
Unfortunately, little is known regarding changes in infarct
material properties with time and reperfusion status, factors that
may affect the optimal properties of the injectable material. It
was our intent to use our MeHA system to isolate one variable
(e.g., injected hydrogel mechanics) to evaluate systematically the
resulting impact on infarct expansion and remodeling. This work
contributes to the development of injectable materials for therapy and provides further insight into the pathobiology that
occurs post-MI. Future work in our laboratory will involve further examination of the change of infarct material properties
(e.g., tissue mechanics) with time and hydrogel (e.g., nondegradable versus degradable) treatment.
A statistical difference in wall thickness in the apex and basilar
infarct regions was evident for both MeHA treatment groups
relative to the infarct control. Importantly, these groups had wall
thicknesses similar to noninfarct controls. This drastic difference
in tissue thickness is further evident upon examination of the
histological images. Although infarct thicknesses increased in
both treatment groups relative to control, signiﬁcantly less infarct
expansion and reduced LV remodeling was seen only with the
MeHA High formulation. This result suggests that the properties
of the injected material (i.e., increased stiffness) may be of greater
importance in stress reduction than infarct stiffening alone.
The global LV geometry was evaluated using real-time 3D
echocardiography. At the 2- and 8-wk time points, an increase
in NEDV and NESV for all groups was observed. However, at
both time points the MeHA High treatment group had smaller
changes in volume than seen in the control infarct and MeHA
Low treatment groups. Furthermore, the differences in both
NEDV and NESV from the 2-wk to the 8-wk time point are
lowest for the MeHA High treatment group. The improvement
in LV volume in the MeHA High treatment group is even clearer
upon the stress testing that was completed before sacriﬁce at
8 wk. These observations are important, because increased endsystolic volume is indicative of adverse effects post-MI (37). LV
function was assessed by monitoring cardiac output and EF
throughout the study. The control infarct group had statistically
different values at the 2-wk and 8-wk follow-ups, whereas both
the MeHA treatment groups did not. As expected, a decrease in
EF was observed for all treatment groups at the 2- and 8-wk
follow-ups. Again, the MeHA High treatment group tended to
have improved EF, which was more dramatic upon stress testing.
The goal of this study was to investigate any salutary effects
associated with differences in the mechanics of the injectable
hydrogels developed to limit infarct expansion and to suppress
the LV remodeling response that occurs post-MI. Our ﬁndings
clearly indicate that the group treated with higher modulus
hydrogel demonstrated less infarct expansion and reduced LV
dilation, as well as improved function when compared with our
lower modulus hydrogel and infarct control groups. In agreement
with the simulations described by Wall et al. (28), we believe that
the higher modulus MeHA hydrogel is better able to stabilize the
myocardium and reduce wall stresses than the lower modulus
MeHA hydrogel. Because the modulus of the tissue/ MeHA Low
composite group is similar to that of the excised cardiac tissue,
it is likely that these values are closer to the passive material
properties of the myocardium during diastole, whereas the modulus of the tissue/MeHA High composite probably is closer to
passive myocardial material properties at end-systole. Because
the increase in wall stress during systole probably drives the
maladaptive remodeling process, the tissue treated with MeHA
High may be more capable of normalizing myocardial stress distribution than tissue treated with MeHA Low.

Statistical Analysis. Data are presented as mean ± SD or mean ± SEM as indicated in the ﬁgure legends. For hydrogel characterization experiments,
differences between groups were assessed using the Student’s t test. Changes
in tissue dimensions and echocardiograph and LV function readings were
assessed using a one-way ANOVA with Tukey’s post hoc evaluation. Echocardiographic and LV function readings were compared using a paired t test for
comparisons with baseline values for a respective group. For all comparisons,
P < 0.05 was considered statistically signiﬁcant.

30 min following infarction. The injection sites were distributed uniformly
within the ischemic territory and located at a depth of ≈2 mm into the
midwall of the myocardium. Echocardiographic data were collected and
analyzed as previously described (23). (Further details on echocardiographic
analysis are given in SI Materials and Methods.)
Echocardiographic and hemodynamic data were collected again at 2 and
8 wk postinfarct. Animals also underwent dobutamine (2.5 and 5.0 mg kg−1
min−1) stress echocardiographic testing at 8 wk. After these evaluations,
animals were killed, the hearts were harvested, and the infarct thickness was
measured with a digital micrometer. Samples also were collected and ﬁxed
for histological analysis using H&E staining and Mason’s trichrome staining.
One MeHA High treatment subject was killed at 24 h postinjection and
processed for histology to evaluate gel distribution in vivo.
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